Gene expression changes associated with erlotinib response in glioma cell lines

European Journal of Cancer

Volumn 49, Issue 7, 2013, Pages 1641-1653

  García Claver, Ainoha ^a   Lorente, Mar ^b   Mur, Pilar ^a   Campos Martín, Yolanda ^a   Mollejo, Manuela ^a   Velasco, Guillermo ^b   Meléndez, Bárbara ^a  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Epidermal growth factor receptor; Erlotinib; Glioblastoma multiforme; Glioma cell lines; Gliomas; MAPK Erk pathway; Microarray expression assays; PI3K Akt pathway; PTEN; Temsirolimus

Indexed keywords

BIRC5 PROTEIN; CTFG PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERCC5 PROTEIN; ERLOTINIB; GAS5 PROTEIN; HISTONE DEACETYLASE 3; POLO LIKE KINASE 1; PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE; CELL DEATH; GENE EXPRESSION; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CLUSTER ANALYSIS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA-BINDING PROTEINS; ENDONUCLEASES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS); QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84876134891     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.01.002     Document Type: Article

References (38)

1. Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2007. Central Brain Tumor Registry of the United States (CBTRUS), Hinsdale, IL. http://www.cbtrus.org/reports/reports.html.
2. D.N. Louis, H. Ohgaki, O.D. Wiestler, and W.K. Cavenee The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol 114 2007 97 109 (Pubitemid 47103521)
3. NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines in Oncology. Central Nervous System Cancers. Version 2.2011. http://www.nccn.org.
4. R. Stupp, W.P. Mason, and M. Van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996 (Pubitemid 40349501)
5. I.K. Mellinghoff, M.Y. Wang, and Y. Vivanco Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors N Engl J Med 2005 353 2005 2012 2024 (Pubitemid 41609094)
6. M. Preusser, E. Gelpi, and A. Rottenfusser Epithelial growth factor receptor inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study J Neurooncol 89 2008 211 218
7. H.S. Friedman, and D.D. Bigner Glioblastoma multiforme and the epidermal growth factor receptor N Engl J Med 353 2005 1997 1999 (Pubitemid 41609092)
8. G. Karpel-Massler, U. Schmidt, and A. Unterberg Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where we do stand? Mol Cancer Res 7 2009 1000 1012
9. P.D. Brown, S. Krishnan, and J.N. Sarkaria Phase I/II Trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177 J Clin Oncol 26 2008 5603 5609
10. J.J. Raizer, L.E. Abrey, and A.B. Lassman A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas Neuro Oncol 12 2010 87 94
11. J.J. Raizer, L.E. Abrey, and A.B. Lassman A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy Neuro Oncol 12 2010 95 103
12. D.A. Reardon, A. Desjardins, and J.J. Vredenburgh Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma Clin Cancer Res 96 2006 219 230
13. J.M. Vaquerizas, J. Dopazo, and R. Diaz-Uriarte DNMAD: web-based diagnosis and normalization for microarray data Bioinformatics 20 2004 3656 3658 (Pubitemid 40136807)
14. L.A. Korde, L. Lusa, and L. McShane Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer Breast Cancer Res Treat 119 2010 685 699
15. G. Dennis, B.T. Sherman, and D.A. Hosack DAVID: Database for Annotation, Visualization, and Integrated Discovery Genome Biol 4 2003 P3
16. W. Huang, B.T. Sherman, and R.A. Lempicki Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources Nat Protoc 4 2009 44 57
17. A. Subramanian, P. Tamayo, and V.K. Mootha Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles Proc Natl Acad Sci USA 102 2005 15545 15550 (Pubitemid 41528093)
18. T.J. Liu, D. Koul, and T. LaFortune NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas Mol Cancer Ther 8 2009 2204 2210
19. D.B. Costa, B.H. Halmos, and A. Kumar BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancer with oncogenic EGFR mutations PLoS Med 4 2007 1669 1680 (Pubitemid 350035456)
20. Y. Gong, R. Sonwar, and K. Politi Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas PLoS Med 4 2007 1655 1668 (Pubitemid 350035455)
21. M.H. Hsieh, Y.F. Fang, and W.C. Chang Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer Lung Cancer 53 2006 311 322
22. J. Lee, I. Vivanco, and R. Beroukhim Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain PLoS Med 3 2006 2264 2273 (Pubitemid 46028511)
23. M.Y. Wang, K.V. Lu, and S. Zhu Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells Cancer Res 66 2006 7864 7869 (Pubitemid 44299148)
24. N.G. Thaker, and I.F. Pollack Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies Expert Rev Neurother 9 2009 1815 1836
25. M.E. Halatsch, U. Schmidt, and J. Behnke-Mursch Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours Cancer Treat Rev 32 2006 74 89 (Pubitemid 43362229)
26. M.E. Halatsch, S. Löw, and T. Hielsher Epidermal growth factor receptor pathway gene expressions and biological response of glioblastoma multiforme cell lines to erlotinib Anticancer Res 28 2008 3725 3728
27. M.E. Halatsch, S. Löw, and K. Mursch Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib J Neurosurg 111 2009 211 218
28. L. Soroceanu, S. Kharbanda, and R. Chen Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma Proc Natl Acad Sci USA 104 2007 3466 3471 (Pubitemid 46364182)
29. L. Zhang, J. Huang, and N. Yang Integrative genomic analysis of phosphatidylinositol 3′-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer Clin Cancer Res 13 2007 5314 5321 (Pubitemid 47510355)
30. M.M. Alonso, R. Alemany, and J. Fueyo E2F1 in gliomas: a paradigm of oncogene addiction Cancer Lett 263 2008 157 163
31. R. Blum, I. Nakdimon, and L. Goldberg E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition Int J Cancer 119 2006 527 538 (Pubitemid 43955705)
32. C. Krakstad, and M. Chekenya Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics Mol Cancer 9 2010 135 149
33. B.T. Hennessy, D.L. Smith, and P.T. Ram Exploiting the PI3K/AKT pathway for cancer drug discovery Nat Rev Drug Discov 4 2005 988 1004
34. H.W. Lo Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas Curr Cancer Drug Targets 10 2010 840 848
35. S. Paternot, and P.P. Roger Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation Cancer Res 69 2009 4577 4581
36. J. Sunayama, K. Matsuda, and A. Sato Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells Stem Cells 28 2010 1930 1939
37. G.T. Williams, M. Mourtada-Maarabouni, and F. Farzaneh A critical role for non-coding RNA GAS5 in growth arrest and rapamycin inhibition in human T-lymphocytes Biochem Soc Trans 39 2011 482 486
38. T. Kino, D.E. Hurt, and T. Ichijo Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor Sci Signal 3 2010 ra08